+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Phenylketonuria Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4997192
  • Report
  • March 2020
  • Region: Global
  • 117 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Censa Pharmaceuticals
  • Codexis Inc.
  • Erytech Pharma SA
  • Homology Medicines Inc.
  • SOM Innovation Biotech SL
  • Synlogic Inc.
  • MORE
The Phenylketonuria Treatment Market is expected to register a CAGR of around 11 % over the forecast period. Growing burden of phenylketonuria disease and the novel treatments emerging related to phenylketonuria is expected to boost the phenylketonuria treatment market growth. According to the National PKU Alliance, the chances of the gene carrier is around one in fifty people and chances of two carriers mating is expected to be around 25%. The degree of affecting the disease is majorly based upon the ethnicity and geographical region. According to the same source, in Ireland around 1 out of 4500 population is diagnosed with it. Similarly, in Asia 1 out of 20,000 is diagnosed with it while in Turkey the incidence is high, i.e., 1 in 4000.

Key Market Trends

Kuvan Phenylketonuria Treatment Segment is Expected to Hold a Major Market Share in the Phenylketonuria Treatment Market

Kuvan is the only drug present currently for the efficient treatment of phenylketonuria. It is being manufactured by BioMarin Pharmaceuticals. It adds more BH4 compound, helps in stimulating phenylalanine hydroxylase enzyme which then breakdown the phenylalanine protein. In 2017, it lost it’s patent and BioMarin Pharmaceuticals gave license to Par Pharmaceuticals to develop a generic version of Kuvan.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America expected to hold a major market share in the global phenylketonuria treatment market due to higher incidence rate of phenylketonuria and the development in treatment type. For instance, Homology Medicines, Inc., a US-based genetic company is developing a gene therapy, HMI-102 for phenylketonuria. Currently, its IND (Investigational New Drug) application has been approved by the USFDA (Food & Drug Administration) and it is undergoing the first phase of clinical trials to test safety and efficacy. According to the National Organization for Rare Disorders, there have been approximately 13,500 to 19,000 newborns diagnosed with phenylketonuria disease in U.S. According to the National Centre for Biotechnology Information published study “Phenylketonuria”, the disease is mostly found in Native Americans and the incidence rate is around 1 in 15,000 people.

Competitive Landscape

The Phenylketonuria Treatment Market is consolidated and consists of few major players. Some of the companies which are currently dominating the market are BioMarin Pharmaceuticals Inc., Censa Pharmaceutical, Synlogic Inc., Erytech Pharma SA, Codexis Inc., SOM Innovation Biotech SL, Homology Medicines Inc. and Ultragenyx (Dimension Therapeutics).

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • 3 months of analyst support.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
2 of 4


  • Censa Pharmaceuticals
  • Codexis Inc.
  • Erytech Pharma SA
  • Homology Medicines Inc.
  • SOM Innovation Biotech SL
  • Synlogic Inc.
  • MORE
1.1 Study Assumptions
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence Rate of Phenylketonuria
4.2.2 Increasing Research and Development Activities in relation to Phenylketonuria Treatment
4.3 Market Restraints
4.3.1 High Cost of Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug
5.1.1 Kuvan
5.1.2 Playnziq
5.1.3 Others
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Rest of the World

6.1 Company Profiles
6.1.1 BioMarin Pharmaceuticals Inc.
6.1.2 Censa Pharmaceuticals
6.1.3 Codexis Inc.
6.1.4 Erytech Pharma SA
6.1.5 Homology Medicines Inc.
6.1.6 Synlogic Inc.
6.1.7 SOM Innovation Biotech SL
6.1.8 Ultragenyx (Dimension Therapeutics)

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • BioMarin Pharmaceuticals Inc.
  • Censa Pharmaceuticals
  • Codexis Inc.
  • Erytech Pharma SA
  • Homology Medicines Inc.
  • Synlogic Inc.
  • SOM Innovation Biotech SL
  • Ultragenyx (Dimension Therapeutics)
Note: Product cover images may vary from those shown